D. Hicklin

Molecular Biology · 2000–2013

A researcher in the Science corpus: 24 papers; trusts 9 researchers and is trusted by 21 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 133 citations into it; #1,856 of 17,773 by trust here, #481 by citations
• Oncology — 75 citations into it; #226 of 1,698 by trust here, #217 by citations
• Cancer Research — 63 citations into it; #231 of 1,780 by trust here, #206 by citations

Whom D. Hicklin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Rakesh K. Jain
2. G. Bergers
3. Shahin Rafii
4. D. Hanahan
5. G. Klement
6. D. Lyden
7. N. Ferrara

Who trusts D. Hicklin overall

1. Y. Fouad
2. Rakesh K. Jain
3. J. Joyce
4. C. Aanei
5. G. J. Yoshida
6. M. Shibuya
7. N. Ferrara
8. L. Ellis
9. N. Vasudev
10. D. Hanahan

Papers from D. Hicklin's perspective

Ordered by how strongly the researchers D. Hicklin trusts endorse each paper. Same corpus, a different order for every researcher.

1. Origins of circulating endothelial cells and endothelial outgrowth from blood. (Journal of Clinical Investigation)
2. Angiogenesis in cancer and other diseases (Nature)
3. Angiopoietin-1 protects the adult vasculature against plasma leakage (Nature Medicine)
4. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells (Journal of Experimental Medicine)
5. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
6. Mechanisms of angiogenesis and arteriogenesis (Nature Medicine)
7. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. (American Journal of Pathology)
8. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
9. Molecular regulation of vessel maturation (Nature Medicine)
10. Regulation of angiogenesis via vascular endothelial growth factor receptors. (Cancer Research)

Their papers

• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006) — 2,588 citations
• Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (2004) — 1,208 citations
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. (2005) — 1,655 citations
• Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. (2004) — 1,344 citations
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche (2005) — 3,287 citations
• Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment (2002) — 684 citations
• Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (2002) — 1,130 citations
• Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells (2001) — 730 citations
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) — 610 citations
• Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes (2006) — 685 citations
• Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth (2001) — 1,994 citations
• Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions (2001) — 1,746 citations
• VEGF-targeted therapy: mechanisms of anti-tumour activity (2008) — 1,684 citations
• Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors (2006) — 602 citations
• Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. (2000) — 2,462 citations
• Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) — 813 citations
• Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. (2013) — 615 citations
• Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. (2005) — 2,955 citations
• Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells (2001) — 781 citations
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. (2008) — 1,137 citations